Kalaris director granted options on 9,000 shares

Kalaris Therapeutics director Leone D. Patterson received a new stock option grant covering 9,000 shares of common stock.

Accepted by SEC EDGAR 06/04/2026 - 04:19 PM EDT Learn about SEC filing dates

Rhea-AI Filing Summary

Kalaris Therapeutics director Leone D. Patterson received a new stock option grant covering 9,000 shares of common stock. The option has an exercise price of $4.72 per share and increases her directly held option position to 9,000 shares. The award was granted on June 3, 2026 and is scheduled to vest in full on the earlier of June 3, 2027 or the company’s 2027 annual stockholder meeting, as long as she continues in service.

Insider Trade Summary

Grant/Award: 9,000 shares

Grant/Award 1 txn

Insider PATTERSON LEONE D

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Stock Option (Right to Buy)	9,000	$0.00	$0.00

Holdings After Transaction: Stock Option (Right to Buy) — 9,000 options (Direct)

Footnotes (1)

1. F1. The option was granted on June 3, 2026. The shares underlying the option are scheduled to vest in full on the earlier of (i) June 3, 2027 or (ii) the date of the Issuer's 2027 Annual Meeting of Stockholders, subject to continued service.

Key Figures

Option grant size: 9,000 shares Exercise price: $4.72 per share Post-grant option holdings: 9,000 shares +2 more

5 metrics

Option grant size 9,000 shares Stock options awarded June 3, 2026

Exercise price $4.72 per share Exercise price of granted stock options

Post-grant option holdings 9,000 shares Total options held following transaction

Option expiration June 2, 2036 Expiration date of stock option grant

Vesting date trigger Earlier of June 3, 2027 or 2027 annual meeting Full vesting schedule, subject to continued service

Key Terms

Stock Option, exercise price, vest in full, Annual Meeting of Stockholders, +1 more

5 terms

Stock Option financial

"The option was granted on June 3, 2026."

A stock option is a contract that gives you the right to buy or sell a company's stock at a specific price within a certain time frame. People use them to potentially make money if the stock's price moves favorably or to protect against losses. It's like holding a coupon that can be used to buy or sell stock at a set price later on.

exercise price financial

"conversion_or_exercise_price: "4.7200""

The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.

vest in full financial

"The shares underlying the option are scheduled to vest in full"

Annual Meeting of Stockholders regulatory

"the Issuer's 2027 Annual Meeting of Stockholders, subject to continued service."

Grant, award, or other acquisition financial

"transaction_code_description: "Grant, award, or other acquisition""

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did Leone D. Patterson report in this Form 4 for Kalaris Therapeutics (KLRS)?

Leone D. Patterson reported receiving a stock option grant for 9,000 shares of Kalaris Therapeutics common stock. The award was granted on June 3, 2026 and represents a compensation-related acquisition, not an open-market stock purchase or sale.

What is the exercise price of Leone Patterson’s new KLRS stock options?

The new stock options have an exercise price of $4.72 per share. This means Patterson can buy up to 9,000 Kalaris Therapeutics common shares at $4.72 once the options vest and are exercised, subject to the award’s vesting and expiration terms.

How many KLRS stock options does Leone Patterson hold after this transaction?

After the reported transaction, Leone Patterson directly holds stock options covering 9,000 shares of Kalaris Therapeutics common stock. The filing does not show additional derivative positions, indicating this grant accounts for the derivative holdings reported in this Form 4.

When do Leone Patterson’s new Kalaris Therapeutics options vest?

The 9,000-share option grant is scheduled to vest fully on the earlier of June 3, 2027 or the company’s 2027 Annual Meeting of Stockholders. Vesting is conditioned on Patterson’s continued service with Kalaris Therapeutics through that vesting date.

Are Leone Patterson’s KLRS Form 4 transactions open-market buys or sells?

The Form 4 reports a compensation-related grant of stock options coded as an acquisition, not open-market trades. There are no reported open-market purchases or sales of Kalaris Therapeutics common stock in this filing, only the new option award.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

PATTERSON LEONE D

(Last) (First) (Middle)

C/O KALARIS THERAPEUTICS, INC.

400 CONNELL DRIVE, SUITE 5500

(Street)

BERKELEY HEIGHTS NEW JERSEY 07922

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Kalaris Therapeutics, Inc. [ KLRS ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
06/03/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	$4.72	06/03/2026		A		9,000		(1)	06/02/2036	Common Stock	9,000	$0	9,000	D

Explanation of Responses:

1. The option was granted on June 3, 2026. The shares underlying the option are scheduled to vest in full on the earlier of (i) June 3, 2027 or (ii) the date of the Issuer's 2027 Annual Meeting of Stockholders, subject to continued service.

	/s/ Brett Hagen, Attorney-in-Fact	06/04/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)